Peroxisome Proliferator Activated Receptor Delta (NUCI or Nuclear Hormone Receptor 1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator Activated Receptor Beta or NR1C2 or PPARD) - Pipeline Review, H2 2016

Published: Sep, 2016 | Pages: 82 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Peroxisome Proliferator Activated Receptor Delta (NUCI or Nuclear Hormone Receptor 1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator Activated Receptor Beta or NR1C2 or PPARD) - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Peroxisome Proliferator Activated Receptor Delta (NUCI or Nuclear Hormone Receptor 1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator Activated Receptor Beta or NR1C2 or PPARD) - Pipeline Review, H2 2016', provides in depth analysis on Peroxisome Proliferator Activated Receptor Delta (NUCI or Nuclear Hormone Receptor 1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator Activated Receptor Beta or NR1C2 or PPARD) targeted pipeline therapeutics. 

The report provides comprehensive information on the Peroxisome Proliferator Activated Receptor Delta (NUCI or Nuclear Hormone Receptor 1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator Activated Receptor Beta or NR1C2 or PPARD), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Peroxisome Proliferator Activated Receptor Delta (NUCI or Nuclear Hormone Receptor 1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator Activated Receptor Beta or NR1C2 or PPARD) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: 
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
*Updated report will be delivered in 48 hours of order confirmation.

Scope

- The report provides a snapshot of the global therapeutic landscape for Peroxisome Proliferator Activated Receptor Delta (NUCI or Nuclear Hormone Receptor 1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator Activated Receptor Beta or NR1C2 or PPARD)
- The report reviews Peroxisome Proliferator Activated Receptor Delta (NUCI or Nuclear Hormone Receptor 1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator Activated Receptor Beta or NR1C2 or PPARD) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Peroxisome Proliferator Activated Receptor Delta (NUCI or Nuclear Hormone Receptor 1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator Activated Receptor Beta or NR1C2 or PPARD) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Peroxisome Proliferator Activated Receptor Delta (NUCI or Nuclear Hormone Receptor 1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator Activated Receptor Beta or NR1C2 or PPARD) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Peroxisome Proliferator Activated Receptor Delta (NUCI or Nuclear Hormone Receptor 1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator Activated Receptor Beta or NR1C2 or PPARD) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Peroxisome Proliferator Activated Receptor Delta (NUCI or Nuclear Hormone Receptor 1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator Activated Receptor Beta or NR1C2 or PPARD)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Peroxisome Proliferator Activated Receptor Delta (NUCI or Nuclear Hormone Receptor 1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator Activated Receptor Beta or NR1C2 or PPARD) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Peroxisome Proliferator Activated Receptor Delta (NUCI or Nuclear Hormone Receptor 1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator Activated Receptor Beta or NR1C2 or PPARD) Overview 8
Therapeutics Development 9
Peroxisome Proliferator Activated Receptor Delta (NUCI or Nuclear Hormone Receptor 1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator Activated Receptor Beta or NR1C2 or PPARD) - Products under Development by Stage of Development 9
Peroxisome Proliferator Activated Receptor Delta (NUCI or Nuclear Hormone Receptor 1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator Activated Receptor Beta or NR1C2 or PPARD) - Products under Development by Therapy Area 10
Peroxisome Proliferator Activated Receptor Delta (NUCI or Nuclear Hormone Receptor 1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator Activated Receptor Beta or NR1C2 or PPARD) - Products under Development by Indication 11
Peroxisome Proliferator Activated Receptor Delta (NUCI or Nuclear Hormone Receptor 1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator Activated Receptor Beta or NR1C2 or PPARD) - Pipeline Products Glance 13
Late Stage Products 13
Early Stage Products 14
Unknown Stage Products 15
Peroxisome Proliferator Activated Receptor Delta (NUCI or Nuclear Hormone Receptor 1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator Activated Receptor Beta or NR1C2 or PPARD) - Products under Development by Companies 16
Peroxisome Proliferator Activated Receptor Delta (NUCI or Nuclear Hormone Receptor 1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator Activated Receptor Beta or NR1C2 or PPARD) - Products under Development by Universities/Institutes 19
Peroxisome Proliferator Activated Receptor Delta (NUCI or Nuclear Hormone Receptor 1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator Activated Receptor Beta or NR1C2 or PPARD) - Therapeutics Assessment 21
Assessment by Monotherapy/Combination Products 21
Assessment by Mechanism of Action 22
Assessment by Route of Administration 24
Assessment by Molecule Type 25
Peroxisome Proliferator Activated Receptor Delta (NUCI or Nuclear Hormone Receptor 1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator Activated Receptor Beta or NR1C2 or PPARD) - Companies Involved in Therapeutics Development 26
Chipscreen Biosciences Ltd 26
Connexios Life Sciences Pvt. Ltd. 27
CymaBay Therapeutics, Inc. 28
Daiichi Sankyo Company, Limited 29
Genfit SA 30
GlaxoSmithKline Plc 31
Inventiva 32
Mitobridge, Inc. 33
Nippon Chemiphar Co., Ltd. 34
T3D Therapeutics, Inc. 35
vTv Therapeutics Inc 36
Peroxisome Proliferator Activated Receptor Delta (NUCI or Nuclear Hormone Receptor 1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator Activated Receptor Beta or NR1C2 or PPARD) - Drug Profiles 37
CNX-013B2 - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
CS-038 - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
Drugs to Modulate PPAR-Delta for Metabolic and Musculoskeletal Disorders - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
elafibranor - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
GW-610742 - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
HPP-593 - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
IVA-337 - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
MBX-8025 - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
NC-2400 - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
Small Molecules to Agonize Pan PPAR for Multiple Sclerosis - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
Small Molecules to Inhibit PPAR Beta and PPAR Delta for Metabolic Disorders, Inflammatory Diseases and Oncology - Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
Small Molecules to Target PPAR delta for Mitochondrial Diseases - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
T3D-959 - Drug Profile 58
Product Description 58
Mechanism Of Action 58
R&D Progress 58
Peroxisome Proliferator Activated Receptor Delta (NUCI or Nuclear Hormone Receptor 1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator Activated Receptor Beta or NR1C2 or PPARD) - Dormant Projects 61
Peroxisome Proliferator Activated Receptor Delta (NUCI or Nuclear Hormone Receptor 1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator Activated Receptor Beta or NR1C2 or PPARD) - Discontinued Products 64
Peroxisome Proliferator Activated Receptor Delta (NUCI or Nuclear Hormone Receptor 1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator Activated Receptor Beta or NR1C2 or PPARD) - Featured News & Press Releases 65
May 31, 2016: CymaBay Therapeutics Announces Top Line Efficacy and Safety Data From Its Phase 2 Study of Mbx-8025 in Patients With Primary Biliary Cholangitis (PBC) 65
Mar 31, 2016: GENFIT to Begin Elafibranor Clinical Program in PBC 66
Mar 30, 2016: Presentations at EASL/ILC 2016 Highlight Progress in NASH Treatment, Biomarker Diagnostics, and Programs Targeting Fibrotic Diseases 67
Mar 17, 2016: CymaBay Therapeutics Announces Positive Results from its Pilot Phase 2 Clinical Study of MBX-8025 in Patients with Homozygous Familial Hypercholesterolemia 68
Mar 10, 2016: GENFIT announces enrollment of first patient in RESOLVE-IT, the pivotal Phase 3 clinical trial of Elafibranor in NASH 70
Feb 25, 2016: Inventiva rewarded for its innovative approach with IVA337 at the 4th Systemic Sclerosis World Congress 71
Feb 11, 2016: Data from phase 2b trial of Genfit elafibranor published in Gastroenterology 71
Jan 28, 2016: IVA337 delivers significant therapeutic advances in fibrosis, a major public health challenge 73
Nov 16, 2015: GENFIT Announces Pivotal Phase 3 Clinical Trial of Elafibranor in NASH Following Regulatory Input 74
Nov 10, 2015: CymaBay Therapeutics Announces the Initiation of a Phase 2 Study of MBX-8025 in Patients With Primary Biliary Cholangitis/Cirrhosis 76
Jun 22, 2015: T3D Therapeutics Receives FDA IND Approval to Begin Phase 2 Clinical Study of T3D-959 in Alzheimer's Patients 77
Jun 08, 2015: T3D Therapeutics Selected by the Alzheimer's Association to Present Pre-Clinical Results of T3D-959 at the 2015 Alzheimer's Association International Conference 77
Apr 24, 2015: New Proof Of Efficacy Of Gft505 In Nash And Positive Expert Opinion 77
Apr 23, 2015: CymaBay Therapeutics Announces the Initiation of a Phase 2 Study of MBX-8025 in Patients With Homozygous Familial Hypercholesterolemia 79
Apr 22, 2015: CymaBay Therapeutics Announces U.S. Orphan Drug Designation for MBX-8025 in Severe Hypertriglyceridemia 80
Appendix 81
Methodology 81
Coverage 81
Secondary Research 81
Primary Research 81
Expert Panel Validation 81
Contact Us 81
Disclaimer 8

List of Tables

Number of Products under Development for, H2 2016 9
Number of Products under Development by Therapy Area, H2 2016 10
Number of Products under Development by Indication, H2 2016 12
Comparative Analysis by Late Stage Development, H2 2016 13
Comparative Analysis by Early Stage Products, H2 2016 14
Comparative Analysis by Unknown Stage Development, H2 2016 15
Number of Products under Development by Companies, H2 2016 16
Products under Development by Companies, H2 2016 17
Products under Development by Companies, H2 2016 (Contd..1) 18
Number of Products under Investigation by Universities/Institutes, H2 2016 19
Products under Investigation by Universities/Institutes, H2 2016 20
Assessment by Monotherapy/Combination Products, H2 2016 21
Number of Products by Stage and Mechanism of Action, H2 2016 23
Number of Products by Stage and Route of Administration, H2 2016 24
Number of Products by Stage and Molecule Type, H2 2016 25
Pipeline by Chipscreen Biosciences Ltd, H2 2016 26
Pipeline by Connexios Life Sciences Pvt. Ltd., H2 2016 27
Pipeline by CymaBay Therapeutics, Inc., H2 2016 28
Pipeline by Daiichi Sankyo Company, Limited, H2 2016 29
Pipeline by Genfit SA, H2 2016 30
Pipeline by GlaxoSmithKline Plc, H2 2016 31
Pipeline by Inventiva, H2 2016 32
Pipeline by Mitobridge, Inc., H2 2016 33
Pipeline by Nippon Chemiphar Co., Ltd., H2 2016 34
Pipeline by T3D Therapeutics, Inc., H2 2016 35
Pipeline by vTv Therapeutics Inc, H2 2016 36
Dormant Projects, H2 2016 61
Dormant Projects (Contd..1), H2 2016 62
Dormant Projects (Contd..2), H2 2016 63
Discontinued Products, H2 2016 64